We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Mayer Brown Advises AstraZeneca On Acquisition

Law360 (April 23, 2007, 12:00 AM EDT) -- Mayer Brown Rowe & Maw LLP is advising AstraZeneca on the antitrust aspects of its $15.8 billion acquisition of MedImmune Inc., announced on Monday.

The all-cash transaction, in which AstraZeneca would acquire all of MedImmune’s common stock for $58 per share, increases the pharmaceutical giant’s pipeline of biotechnology drugs by 45 projects to 163 projects.

“This acquisition represents a transformational step to deliver our biologics strategy sooner than anticipated,” said David Brennan, chief executive officer of AstraZeneca. “It creates a leading fully integrated biologics and vaccines...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.